Chandra Loke

Hem/Onc MD , Baystate -UMass Chan

[Vaishali Sanchorawala @vsanchorawala]

Treatment of systemic amyloidosis is evolving rapidly. This comprehensive review highlights recent advances in AL and ATTR amyloidosis. @BU_Amyloidosis
Systemic light chain and transthyretin amyloidosis—treatment advanceme... https://t.co/ubuUFstcUt

[Haematologica @Haematologica]

What is the optimal treatment strategy for elderly patients with Philadelphia chromosome-positive ALL?
A new review explores evolving approaches in a rapidly changing therapeutic landscape.
Read more in Haematologica
https://t.co/bi2HCS9kp9

[Kate Cwynarski @CwynKate]

End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology https://t.co/63890j5Upb

[Keith W Pratz MD @PratzKW]

Happy to share our work on the impact of antifungal prophylaxis(AFP) on outcomes in newly diagnosed AML treated with venetoclax based therapy. In a real world analysis of 1524 patients, use of AFP was associated with inferior survival(HR 1.19, P=0.004). https://t.co/gyVFI8mjWw

[Chandra Loke @ChandraLokeMD]

@VincentRK @myelomaMD @mtmdphd @MyelomaTeacher @IMFmyeloma Have a patient who received RVd followed by ixa maintainence as she couldn’t tolerate len / velcade and now with relapse - technically not len refractory..

[Chandra Loke @ChandraLokeMD]

@VincentRK @myelomaMD @mtmdphd @MyelomaTeacher @IMFmyeloma Dara naive , second relapse - have to be Len refractory to be eligible for Tec-dara ?

[The New Yorker @NewYorker]

Tatiana Schlossberg, the daughter of Caroline Kennedy, had just given birth when she was diagnosed with a rare form of leukemia. She writes about her fear of adding another tragedy to her family’s life. https://t.co/UmCzrI9QiM

[ASH @ASH_hematology]

The highly anticipated #ASH25 late-breaking abstracts have been posted: https://t.co/o8zFqe0x1v

👏#ASHKudos to the presenters!

Discover more important and novel research at the 67th ASH Annual Meeting. It's not too late to register! #MedTwitter #Hematology #HemeOnc

[Chandra Loke @ChandraLokeMD]

#ASH25

[Uriel Suárez @UsuarezMD]

Intermediate-Dose Cytarabine as Postinduction AML Therapy | NEJM Evidence https://t.co/l3wXJXfh54

[Eddie Cliff @Eddie_Cliff]

David Scott’s @BCCancer algorithm for treatment of newly-diagnosed DLBCL based on recent Canadian recommendation for polatuzumab reimbursement for ABC-subtype DLBCL

#lymsm #18ICML @AshAlizadeh

[NEJM @NEJM]

Original Article: Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma (MIDAS phase 3 trial) https://t.co/GXEKDda6he

#ASCO25 | @ASCO

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: MIDAS study of MRD-guided consolidation strategy in pts eligible for ASCT finds those who were MRD-negative @ 10-5 post-induction % w/ pre-maintenance MRD- status at 10-6 sensitivity was not higher with ASCT vs. Isa-KRd: https://t.co/hQ9HybmJaf. #mmsm

[Blood Journals Portfolio @BloodPortfolio]

Of the 12 patients who reversed from MRD negative to MRD positive and restarted maintenance, 4 progressed and all remained alive. https://t.co/jzgR4ByyRQ #lymphoidneoplasia #multiplemyeloma

[Uriel Suárez @UsuarezMD]

Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | New England Journal of Medicine https://t.co/76Q8K7HfIy

[Ximena Jordan Bruno @XimeJordan]

Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review | Blood Advances | American Society of Hematology https://t.co/To1MAeRqkD

[Vincent Rajkumar @VincentRK]

Just out: My 2024 Update on diagnosis, risk stratification, and treatment of myeloma.
#AJH @MayoCancerCare

10 Tables; Algorithms
Includes current data including trials published this month! #ASCO24

https://t.co/B9nLdpfbLK

[Blood Journals Portfolio @BloodPortfolio]

For decades, the only option for newly diagnosed acute myelogenous leukemia #AML that provided a path to remission and long-term disease-free survival required initial treatment with intensive induction therapy. https://t.co/HXKTLml7tx

[Chandra Loke @ChandraLokeMD]

@baystatehemeonc Congratulations to Swarna and @NamSharmaMD 👏🏼👏🏼

[UMass Chan - Baystate Hematology Oncology @baystatehemeonc]

Baystate past and present residents, fellows and faculty got together at #ASH24. How wonderful to see everyone together!